Upharmacia August 2017
CIS PHARMA NEWS
A zerbaijan
— — Bulgarian pharmaceutical companies
take an interest in Pirallahi industrial
park and consider possibilities of
cooperation in pharmaceutical sphere.
B elarus
— — Indian company Chokhani Pharma
proposed Belarus to establish joint
manufacturing of drugs against
hepatitis, including sofosbuvir.
— — In 1H2017, the share of Belarussian drugs on the
internal market increased to 57.2% in values, the
MOH’s official reported.
— — The government closed out Pharmaceutical
Industry Department and subordinated four
state companies (JSC Borimed, JSC Nesvizh
Plant of Medical Preparations, JSC Ekzon and JSC
Ferane) to Management company of the holding
Belpharmprom.
R ussia
— — Janssen intends to localize in Russia
the production of the range of
innovative drugs for the treatment
of malignant blood diseases including Imbruvica
(ibrutinib).
— — Roche signed agreement on localization of
obinutuzumab at the facilities of Pharmstandard
company in Ufa. First series of the drug are
expected to be produced in the end of 2018.
— — Venture Biotech Fund Primer Capital invested in the
development of the drug by Gemopharm company
for the treatment of multiple myeloma. The drug
has already shown high efficacy in vivo. It is being
prepared to pre-clinical trials.
Zone in Port Said.
— — In 4Q2017, Pharmsyntez intends to launch onto the
market the new portfolio of hypoglycemic drugs,
which will include gliclazide, repaglinide, metformin,
glibenclamide, glimepiride, glycidone, glibenclamide
+ metformin.
K azakhstan
— — LLC R-Pharm Kazakhstan, LLC
ULNANOTECH and LLC TestGen
signed cooperation agreement to
implement innovative developments in non-invasive
prenatal diagnosis and diagnosis of cancer in the
Republic of Kazakhstan.
— — Within the state program for industrial
development, three new pharmaceutical
plants will be opened in Kazakhstan by the end
of 2019. Hikma CIS will invest KZT 6.5 bn to
construct plant in Almaty. JuldyzKenan Co., LTD
is to launch manufacturing of disposable medical
products made of polymers worth KZT 1.7 bn.
ASTANA PHARMBIOSYNTESIS will produce vital
pharmaceutical preparations at the facilities worth
KZT 32.9 bn.
— — Teva does not plan to close its representative office
in Kazakhstan, as it has long-term plans for presence
on the market, the company’s officials reported.
Teva was 7th company on Kazakh market in 2016
with 278 products represented.
— — Single distributor SK-Parmacia reached agreement
with 23 local companies on the procurement of
523 positions of drugs and 389 positions of medical
devices. These products will be procured for state
needs during next 10 years. The agreement is aimed
to guarantee the sales of manufactured products
and thereby to support local manufacturers.
— — BIOCAD company will build a production complex in
Pushkin district in St. Petersburg. It will include the
center for pre-clinical trials, as well as production of
substances and finished drugs. The investments to
amount RUB 3bn.
— — BIOCAD company plans to open representative
office in Egypt by the end of 2017 with intention to
enter the whole market of Near East. The company
may localize manufacturing in Russian Industrial
10
www.upharma-c.com